Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

07:00	Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth (GlobeNewswire)
19.11.24	Novartis ranks first in 2024 Access to Medicine Index (GlobeNewswire)
29.10.24	Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile (GlobeNewswire)
29.10.24	Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance (GlobeNewswire)
29.10.24	Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben (GlobeNewswire)
27.10.24	Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial (GlobeNewswire)
24.10.24	Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (GlobeNewswire)
18.10.24	Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer (GlobeNewswire)
17.09.24	FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer (GlobeNewswire)
16.09.24	Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer (GlobeNewswire)
28.08.24	Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk (GlobeNewswire)
08.08.24	Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) (GlobeNewswire)
18.07.24	Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance (GlobeNewswire)
18.07.24	Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben (GlobeNewswire)
31.05.24	Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML (GlobeNewswire)
31.05.24	Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria (GlobeNewswire)
25.05.24	Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio (GlobeNewswire)
25.05.24	Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo (GlobeNewswire)
16.05.24	Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash (GlobeNewswire)
15.05.24	Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA (GlobeNewswire)
24.04.24	Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria (GlobeNewswire)
23.04.24	Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors (GlobeNewswire)
23.04.24	Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht (GlobeNewswire)
23.04.24	Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised (GlobeNewswire)
17.04.24	Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis (GlobeNewswire)
15.04.24	New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) (GlobeNewswire)
11.04.24	Novartis tender offer for MorphoSys AG commences (GlobeNewswire)
06.04.24	New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting (GlobeNewswire)
22.03.24	Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)
05.03.24	Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
05.03.24	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
04.03.24	Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA (GlobeNewswire)
05.02.24	Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash (GlobeNewswire)
31.01.24	Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts (GlobeNewswire)
31.01.24	Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen (GlobeNewswire)
19.01.24	Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors (GlobeNewswire)
08.01.24	Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia (GlobeNewswire)
05.01.24	Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis (GlobeNewswire)
11.12.23	Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) (GlobeNewswire)
11.12.23	Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)
08.12.23	Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions (GlobeNewswire)
06.12.23	Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH (GlobeNewswire)
28.11.23	Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day (GlobeNewswire)
20.11.23	Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH (GlobeNewswire)
09.11.23	Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 (GlobeNewswire)
31.10.23	FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade (GlobeNewswire)
30.10.23	Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) (GlobeNewswire)
24.10.23	Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht (GlobeNewswire)
24.10.23	Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance (GlobeNewswire)
23.10.23	Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane settin (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	545.00	2.64 %	K V
Logitech Intl	69.54	1.52 %	K V
Swiss Re	127.40	1.15 %	K V
Roche Hldg G	250.90	0.68 %	K V
Givaudan	3’886.00	0.60 %	K V
Sonova Hldg	302.20	-0.40 %	K V
Nestle	76.20	-0.42 %	K V
Lonza Grp	514.40	-0.50 %	K V
Kuehne+Nagel Int	206.90	-0.62 %	K V
CieFinRichemont	117.15	-1.22 %	K V

mehr

12:26		Anleger in Frankfurt halten sich zurück: SDAX verliert am Mittag
12:26		Schwacher Handel: Euro STOXX 50 am Donnerstagmittag in der Verlustzone
12:26		Freundlicher Handel: DAX notiert am Donnerstagmittag im Plus
12:26		LUS-DAX-Handel aktuell: LUS-DAX liegt mittags im Minus
12:26		Donnerstagshandel in Zürich: SPI zeigt sich mittags schwächer
12:26		Zuversicht in Zürich: SMI legt zu
12:26		Gewinne in Zürich: So performt der SLI am Mittag
11:35		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus